CBER, ORA Saw FY 2020 User Fee Spending Drop Even As COVID Strained US FDA’s Resources
Executive Summary
ORA continued to spend user fee dollars despite its inability to travel for facility inspections, while CBER found little generic and biosimilar work during FY 2020.
You may also be interested in...
BsUFA III Negotiations Nearly Done; Commitment Letter Being Written
Supplement approval timeline and regulatory science issues apparently have been resolved.
BsUFA III Negotiations Nearly Done; Commitment Letter Being Written
Supplement approval timeline and regulatory science issues apparently have been resolved.
Forty-Eight US FDA Drug Application Decisions Delayed By Pandemic's Deferred Inspections
US FDA 'resilience' report charts how inspection backlog grew and impacted approvals and compliance follow-up.